Scimar
About this raise
Scimar is raising funds on Texture Capital through Reg A+ crowdfunding. The company discovered the hepatalin hormone and is revolutionizing the prevention, diagnosis, and treatment of type 2 diabetes. Scimar is developing medical interventions based on the science of hepatalin to handle excess glucose in the body and bring an end to type 2 diabetes. The company has currently conceived four products, including SciMar NuPa Test, SciMar NuPa Daily, SciMar NuPa Renew, and Hepatalin-S, and plans to grow more. Dr. W. Wayne Lautt and Mick Lautt founded Scimar in 2009. The current crowdfunding campaign has a maximum target of $55 million. The campaign proceeds will be used for research and development, expanded infrastructure, cost of capital, facilities, operations, brand building, and accounting expenses.
Investment Overview
Invested $358,639 :
Deal Terms
Company & Team
Company
- Year Founded
- 2009
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $19,630,000
- Grants
- $17,300,000
- VC Backed?
- No
Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
06/26/2024 | Texture Capital | $478,866,592 | $358,639 | Equity - Common | Funded | RegA+ |